BIOS

BIOS Health uses data-driven insights from the nervous system to build neural digital therapies - the next big trend in precision medicines. The human nervous system carries vast quantities of data, and BIOS’ ability to precisely link nerve activity to specific conditions through the discovery of their neural biomarkers is a game changer for precision medicine. BIOS’ research could hold the key to new treatments for conditions including hypertension, diabetes, rheumatoid arthritis, and even diseases of the brain itself such as Parkinson’s or Alzheimer’s. BIOS is positioned to provide the neural code on which a new generation of treatments can be built that can enable millions of people suffering from chronic diseases to improve their quality of life.

Co-founded by Cambridge University researchers Emil Hewage, a computational neuroscientist, and Oliver Armitage, a biomechanical engineer, BIOS is made up of a wide range of experts from neuroscience, machine learning, software engineering, applied biomaterials, biotechnology and medicine. Advisors include Oxford University Professors David Paterson and Tim Denison, CEO of Candel Therapeutics Paul Peter Tak, and IQVIA VP of Genomic and Precision Medicine Joanne Hackett (Chair of the BIOS Board).

BIOS headquartered in Europe, operates in the Artificial Intelligence (AI), Machine Learning, Health Care, Medical, Medical Device, Bioinformatics, Human Computer Interaction sector. The company focuses on Artificial Intelligence (AI) and has secured $13.1B in funding across 280 round(s). With a team of 11-50 employees, BIOS is actively contributing to advancements in Artificial Intelligence (AI). Their latest funding round, Non Equity Assistance - BIOS, raised $Unknown amount. Discover more about their projects, partnerships, and impact on our platform.